Silexan in the Treatment of Posttraumatic Stress Disorder Trial

PHASE3RecruitingINTERVENTIONAL
Enrollment

224

Participants

Timeline

Start Date

August 26, 2024

Primary Completion Date

February 28, 2027

Study Completion Date

March 31, 2027

Conditions
Post Traumatic Stress Disorder
Interventions
DRUG

Silexan

Participants in the Silexan arm will take two over-encapsulated capsules, each containing 80 mg Silexan, daily orally in the morning in addition to their usual medications. No modifications of allocated interventions will be made for any trial participants; if appropriate (i.e following the emergence of adverse events) participants will be withdrawn from the intervention.

OTHER

Placebo

Participants in the placebo arm will take two capsules containing an inert placebo daily orally in the morning in addition to their usual medications. The placebo capsules will contain a sub-therapeutic amount of lavender oil to mimic the odor of the experimental drug (Silexan).

Trial Locations (4)

3004

RECRUITING

Ramsay Clinic Albert Road, Melbourne

3084

RECRUITING

Austin Health, Heidelberg

3220

RECRUITING

Deakin University, Geelong

5053

RECRUITING

University of Melbourne, Carlton

All Listed Sponsors
collaborator

University of Melbourne

OTHER

collaborator

Ramsay Clinic Albert Road

UNKNOWN

lead

Deakin University

OTHER